Quizartinib Added to Standard Chemotherapy Improves Event-Free and Overall Survival in Newly Diagnosed FLT3‑ITD–Negative AML: Findings from the Phase II QUIWI Trial
– The phase II randomized, double‑blind QUIWI trial (n=273) tested quizartinib 60 mg daily added to standard induction and consolidation chemotherapy followed by maintenance in adults (18–70 years) with newly diagnosed FLT3‑ITD–negative AML.
– Median event‑free survival (EFS) was 20.4 months with quizartinib vs 9.9 months with placebo (P = .046). Median overall survival (OS) was not reached with quizartinib vs 29.3 months with placebo (P = .012); 3‑year OS rates were 60.8% vs 45.7%.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
